Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) will hold its 2025 Annual General Meeting on December 23, 2025 at 10:30 a.m. local time at its Shanghai office: 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai.

The AGM agenda includes ratifying the appointment of Ernst & Young Hua Ming LLP as auditor for the year ending December 31, 2025, re-election of Feng Deng and Licen Lisa Xu as directors, and authorizing directors to take actions to effect those resolutions. The board recommends shareholders and ADS holders vote in favor.

The record date for shareholders entitled to notice is December 1, 2025 (New York time). ADS holders must instruct Citibank, N.A. to vote underlying Class A shares. Burning Rock filed its Form 20-F with audited financials for year ended December 31, 2024.

News Market Reaction

-12.04%

6 alerts

-12.04% News Effect

-21.7% Trough in 22 hr 45 min

-$34M Valuation Impact

$247M Market Cap

1.3x Rel. Volume

On the day this news was published, BNR declined 12.04%, reflecting a significant negative market reaction. Argus tracked a trough of -21.7% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $34M from the company's valuation, bringing the market cap to $247M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

AGM date: December 23, 2025 Record date: December 1, 2025 Par value: US$0.0002 per share +5 more

8 metrics

AGM date December 23, 2025 Scheduled annual general meeting in Shanghai at 10:30 a.m. local time

Record date December 1, 2025 Cut-off for shareholders/ADS holders entitled to AGM notice and voting

Par value US$0.0002 per share Par value of Class A and Class B ordinary shares

Fiscal year-end December 31, 2024 Year covered by filed Form 20‑F with audited financials

Current price $17.05 Before AGM notice; within 52-week range of $2.18–$23.59

52-week low $2.18 Stock had previously traded significantly lower within past year

52-week high $23.59 Shares remained below this level pre‑AGM announcement

Market cap $183,355,130 Pre‑AGM market capitalization for Burning Rock

Market Reality Check

Price: $31.00 Vol: Volume 35,695 is at 0.54x...

low vol

$31.00 Last Close

Volume Volume 35,695 is at 0.54x the 20-day average of 65,788, suggesting muted trading ahead of the AGM. low

Technical Shares trade above the 200-day MA of 7.25 at a price of 17.05, after a sharp rebound from the 2.18 52-week low but still below the 23.59 52-week high.

Peers on Argus

BNR showed a modest 0.12% gain pre‑AGM while peers like PRE (+7.8%), XGN (+0.98%...

BNR showed a modest 0.12% gain pre‑AGM while peers like PRE (+7.8%), XGN (+0.98%), BDSX (+0.75%), and FONR (+0.52%) also traded higher, but no momentum scanner signals or same‑day peer news indicate a broad coordinated sector move.

Historical Context

4 past events · Latest: Dec 01 (Neutral)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	AGM announcement	Neutral	-12.0%	AGM scheduling, auditor ratification and director re‑election proposals.
Nov 20	Earnings update	Positive	-3.1%	Q3 2025 results with revenue growth and narrower net loss.
Sep 24	Regulatory approval	Positive	-0.8%	Japan MHLW approval of OncoScreen Plus CDx for capivasertib.
Sep 08	Earnings update	Positive	+9.2%	Q2 2025 results with higher revenue, margin gains, lower expenses.

Pattern Detected

Recent news, including regulatory and earnings updates, often saw negative or muted price reactions, with only one of four tracked events aligning positively with seemingly constructive fundamentals.

Recent Company History

Over the last few months, Burning Rock reported improving fundamentals, with Q2 and Q3 2025 earnings showing revenue growth, rising gross margins, and sharply narrower net losses. The company also secured Japan MHLW approval for its OncoGuide OncoScreen Plus CDx system and advanced registration in China. Despite these milestones, price reactions were mixed, with several positive updates followed by negative or muted moves. Today’s AGM notice on December 23, 2025 fits into a period where operational progress did not consistently translate into supportive short‑term trading.

Market Pulse Summary

The stock dropped -12.0% in the session following this news. A negative reaction despite this mainly...

Analysis

The stock dropped -12.0% in the session following this news. A negative reaction despite this mainly procedural AGM announcement would fit a pattern where BNR’s positive or neutral news previously coincided with weak price responses, as seen after recent earnings and regulatory approvals. With shares already below the $23.59 52-week high but well above the $2.18 low, a sharp decline could reflect profit‑taking after a large rebound or renewed skepticism about translating operational progress into sustained performance, rather than the AGM mechanics alone.

Key Terms

next generation sequencing, precision oncology, auditor, american depositary shares, +2 more

6 terms

next generation sequencing medical

"focusing on the application of next generation sequencing (NGS) technology"

A collection of advanced laboratory methods that read and map large amounts of DNA or RNA quickly and at lower cost than older techniques; think of it as scanning thousands of pages of a book at once instead of reading one page at a time. Investors care because it accelerates drug development, enables precise diagnostics and personalized treatments, and can create recurring revenue from tests, instruments, and data services as adoption expands.

precision oncology medical

"NGS technology in the field of precision oncology"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

auditor financial

"appointment of Ernst & Young Hua Ming LLP as auditor of the Company"

An auditor is an independent professional who examines a company’s financial records, accounting systems, and internal controls to confirm that reported numbers are accurate and follow the rules. For investors, an auditor’s review is like a third‑party inspector for a house: it reduces the risk of hidden problems, makes financial statements more trustworthy, and helps investors judge whether a company’s reported results reflect reality.

american depositary shares financial

"shareholders and holders of American depositary shares (“ADSs”)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

par value financial

"each with a par value of US$0.0002 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

form 20-f regulatory

"filed its annual report on Form 20-F containing the complete audited"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

AI-generated analysis. Not financial advice.

GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 23, 2025 at 10:30 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company’s website, within Investors Relation section, at https://ir.brbiotech.com.

The AGM will be held for the following proposals:

1. as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
   
2. as an ordinary resolution, THAT Feng Deng and Licen Lisa Xu be re-elected as directors of the Company; and
   
3. as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
   

The board of directors of the Company fully supports these proposals and recommends that shareholders and holders of American depositary shares (“ADSs”) vote in favor of these proposals.

The board of directors of the Company has fixed the close of business on December 1, 2025 (New York time) as the record date for determining the shareholders entitled to receive notice of the AGM or any adjournment or postponement thereof. Holders of record of the Company’s Class A ordinary shares or Class B ordinary shares, each with a par value of US$0.0002 per share, at the close of business on the record date are entitled to attend the AGM and any adjournment or postponement thereof. Holders of record of ADSs as of the close of business on December 1, 2025 (New York time) who wish to exercise their voting rights for the underlying Class A ordinary shares must give voting instructions to Citibank, N.A., the depositary of the ADSs.

The board of directors of the Company fully supports the proposed resolutions and recommends that shareholders and holders of ADSs vote in favor of the proposed resolutions.

The Company has filed its annual report on Form 20-F containing the complete audited financial statements and the report of auditors for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed on the Company’s website at https://ir.brbiotech.com, and on SEC’s website at http://www.sec.gov.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

FAQ

When and where is Burning Rock Biotech's (BNR) 2025 Annual General Meeting?

The AGM is on December 23, 2025 at 10:30 a.m. local time at the company's Shanghai office: 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai.

What resolutions will shareholders vote on at Burning Rock (BNR) AGM on December 23, 2025?

Shareholders will vote to ratify Ernst & Young Hua Ming LLP as auditor for 2025, re-elect Feng Deng and Licen Lisa Xu, and authorize directors to implement the resolutions.

Who is eligible to vote at Burning Rock (BNR) AGM and what is the record date?

Holders of Class A or Class B ordinary shares and ADS holders of record at the close of business on December 1, 2025 (New York time) are entitled to notice; ADS holders must instruct Citibank, N.A. to vote underlying Class A shares.

Where can investors find the AGM notice, proxy form, and Burning Rock (BNR) annual report?

The AGM notice, proxy form, and the Form 20-F with audited financials for year ended December 31, 2024 are available on Burning Rock's investor relations website at https://ir.brbiotech.com and on http://www.sec.gov.

How should ADS holders of Burning Rock (BNR) submit voting instructions for the December 23, 2025 AGM?

ADS holders must provide voting instructions to Citibank, N.A., the depositary, to exercise voting rights for the underlying Class A ordinary shares.